Human methylome studies SRP028577 Track Settings
 
Large-scale hypomethylated blocks associated with Epstein-Barr virus-induced B-cell immortalization [Bisulfite-seq] [Activated B-cells, Activated B-cells day 16, Activated B-cells week 3, EBV transformed B-cells, EBV transformed B-cells 16 days post infection, EBV transformed B-cells 3 weeks post infection, Resting B-cells]

Track collection: Human methylome studies

+  All tracks in this collection (463)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       HMR       CpG methylation ▾       PMD       CpG reads ▾      
Select subtracks by views and experiment:
 All views AMR  HMR  CpG methylation  PMD  CpG reads 
experiment
SRX332376 
SRX332377 
SRX332378 
SRX332379 
SRX332380 
SRX332381 
SRX332382 
SRX332383 
SRX332384 
SRX332385 
SRX332386 
SRX332388 
SRX332389 
SRX332390 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX332376  HMR  Activated B-cells / SRX332376 (HMR)   Schema 
hide
 Configure
 SRX332376  CpG methylation  Activated B-cells / SRX332376 (CpG methylation)   Schema 
hide
 SRX332377  HMR  Activated B-cells / SRX332377 (HMR)   Schema 
hide
 Configure
 SRX332377  CpG methylation  Activated B-cells / SRX332377 (CpG methylation)   Schema 
hide
 SRX332378  HMR  Activated B-cells / SRX332378 (HMR)   Schema 
hide
 Configure
 SRX332378  CpG methylation  Activated B-cells / SRX332378 (CpG methylation)   Schema 
hide
 SRX332379  HMR  Resting B-cells / SRX332379 (HMR)   Schema 
hide
 Configure
 SRX332379  CpG methylation  Resting B-cells / SRX332379 (CpG methylation)   Schema 
hide
 SRX332380  HMR  Resting B-cells / SRX332380 (HMR)   Schema 
hide
 Configure
 SRX332380  CpG methylation  Resting B-cells / SRX332380 (CpG methylation)   Schema 
hide
 SRX332381  HMR  Resting B-cells / SRX332381 (HMR)   Schema 
hide
 Configure
 SRX332381  CpG methylation  Resting B-cells / SRX332381 (CpG methylation)   Schema 
hide
 SRX332382  HMR  EBV transformed B-cells / SRX332382 (HMR)   Schema 
hide
 Configure
 SRX332382  CpG methylation  EBV transformed B-cells / SRX332382 (CpG methylation)   Schema 
hide
 SRX332384  HMR  EBV transformed B-cells / SRX332384 (HMR)   Schema 
hide
 Configure
 SRX332383  CpG methylation  EBV transformed B-cells / SRX332383 (CpG methylation)   Schema 
hide
 SRX332385  HMR  Activated B-cells day 16 / SRX332385 (HMR)   Schema 
hide
 Configure
 SRX332384  CpG methylation  EBV transformed B-cells / SRX332384 (CpG methylation)   Schema 
hide
 SRX332386  HMR  Activated B-cells day 16 / SRX332386 (HMR)   Schema 
hide
 Configure
 SRX332385  CpG methylation  Activated B-cells day 16 / SRX332385 (CpG methylation)   Schema 
hide
 Configure
 SRX332386  CpG methylation  Activated B-cells day 16 / SRX332386 (CpG methylation)   Schema 
hide
 SRX332388  HMR  Activated B-cells week 3 / SRX332388 (HMR)   Schema 
hide
 Configure
 SRX332388  CpG methylation  Activated B-cells week 3 / SRX332388 (CpG methylation)   Schema 
hide
 SRX332389  HMR  EBV transformed B-cells 16 days post infection / SRX332389 (HMR)   Schema 
hide
 Configure
 SRX332389  CpG methylation  EBV transformed B-cells 16 days post infection / SRX332389 (CpG methylation)   Schema 
hide
 SRX332390  HMR  EBV transformed B-cells 3 weeks post infection / SRX332390 (HMR)   Schema 
hide
 Configure
 SRX332390  CpG methylation  EBV transformed B-cells 3 weeks post infection / SRX332390 (CpG methylation)   Schema 
    

Study title: Large-scale hypomethylated blocks associated with Epstein-Barr virus-induced B-cell immortalization [Bisulfite-seq]
SRA: SRP028577
GEO: GSE49627
Pubmed: 24068705

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX332376 Activated B-cells 0.795 5.3 43442 1295.8 32 1241.9 1709 20526.3 0.983 title: GSM1202804 Activated B-cells from individual B1, Homo sapiens, Bisulfite-Seq; {"source_name": "Activated B-cells", "individual/donor_id": "B1", "sample_group": "CD40 activation", "timepoint": "day6 following CD40 activation"}
SRX332377 Activated B-cells 0.792 5.9 43116 1278.6 33 1219.7 1656 17313.0 0.982 title: GSM1202805 Activated B-cells from individual B2, Homo sapiens, Bisulfite-Seq; {"source_name": "Activated B-cells", "individual/donor_id": "B2", "sample_group": "CD40 activation", "timepoint": "day6 following CD40 activation"}
SRX332378 Activated B-cells 0.801 7.0 46182 1209.1 49 1254.8 1988 16031.7 0.985 title: GSM1202806 Activated B-cells from individual B3, Homo sapiens, Bisulfite-Seq; {"source_name": "Activated B-cells", "individual/donor_id": "B3", "sample_group": "CD40 activation", "timepoint": "day6 following CD40 activation"}
SRX332379 Resting B-cells 0.805 6.7 44619 1253.5 33 1214.3 1837 22799.7 0.981 title: GSM1202807 Resting B-cells from individual B1, Homo sapiens, Bisulfite-Seq; {"source_name": "Resting B-cells", "individual/donor_id": "B1", "sample_group": "Resting", "timepoint": "day0"}
SRX332380 Resting B-cells 0.823 4.3 40464 1318.7 18 1415.0 1281 26797.1 0.977 title: GSM1202808 Resting B-cells from individual B2, Homo sapiens, Bisulfite-Seq; {"source_name": "Resting B-cells", "individual/donor_id": "B2", "sample_group": "Resting", "timepoint": "day0"}
SRX332381 Resting B-cells 0.823 6.1 42396 1284.5 38 1210.0 1628 18902.3 0.948 title: GSM1202809 Resting B-cells from individual B3, Homo sapiens, Bisulfite-Seq; {"source_name": "Resting B-cells", "individual/donor_id": "B3", "sample_group": "Resting", "timepoint": "day0"}
SRX332382 EBV transformed B-cells 0.655 7.3 39245 2351.4 52 1101.1 505 2335673.5 0.977 title: GSM1202810 EBV transformed B-cells from Individual B1, Homo sapiens, Bisulfite-Seq; {"source_name": "EBV transformed B-cells", "individual/donor_id": "B1", "sample_group": "EBV transformation into LCL", "timepoint": "week6 following EBV infection"}
SRX332383 EBV transformed B-cells 0.625 6.7 41333 4823.0 26 1344.5 870 1694603.4 0.986 title: GSM1202811 EBV transformed B-cells from Individual B2, Homo sapiens, Bisulfite-Seq; {"source_name": "EBV transformed B-cells", "individual/donor_id": "B2", "sample_group": "EBV transformation into LCL", "timepoint": "week6 following EBV infection"}
SRX332384 EBV transformed B-cells 0.645 3.5 31317 3483.2 21 1154.5 615 2176456.7 0.986 title: GSM1202812 EBV transformed B-cells from Individual B3, Homo sapiens, Bisulfite-Seq; {"source_name": "EBV transformed B-cells", "individual/donor_id": "B3", "sample_group": "EBV transformation into LCL", "timepoint": "week6 following EBV infection"}
SRX332385 Activated B-cells day 16 0.799 3.6 39896 1323.7 62 1146.8 874 28498.9 0.995 title: GSM1202813 Activated B-cells from individual B4, day 16, Homo sapiens, Bisulfite-Seq; {"source_name": "Activated B-cells_day 16", "individual/donor_id": "B4", "sample_group": "CD40 activation", "timepoint": "day16 following CD40 activation"}
SRX332386 Activated B-cells day 16 0.776 7.7 50984 1032.2 390 984.2 1193 19672.7 0.994 title: GSM1202814 Activated B-cells from individual B5, day 16, Homo sapiens, Bisulfite-Seq; {"source_name": "Activated B-cells_day 16", "individual/donor_id": "B5", "sample_group": "CD40 activation", "timepoint": "day16 following CD40 activation"}
SRX332388 Activated B-cells week 3 0.752 4.8 44124 1165.9 450 1016.2 971 24110.2 0.994 title: GSM1202816 Activated B-cells from individual B5, week 3, Homo sapiens, Bisulfite-Seq; {"source_name": "Activated B-cells_week 3", "individual/donor_id": "B5", "sample_group": "CD40 activation", "timepoint": "week3 following CD40 activation"}
SRX332389 EBV transformed B-cells 16 days post infection 0.753 8.0 47715 1070.2 309 971.0 1410 16788.8 0.995 title: GSM1202817 EBV transformed B-cells from Individual B4, 16 days post infection, Homo sapiens, Bisulfite-Seq; {"source_name": "EBV transformed B-cells_16 days post infection", "individual/donor_id": "B4", "sample_group": "EBV transformation into LCL", "timepoint": "day16 following CD40 activation"}
SRX332390 EBV transformed B-cells 3 weeks post infection 0.762 5.6 40503 1248.7 59 1075.3 1025 19826.1 0.995 title: GSM1202818 EBV transformed B-cells from Individual B4, 3 weeks post infection, Homo sapiens, Bisulfite-Seq; {"source_name": "EBV transformed B-cells_3 weeks post infection", "individual/donor_id": "B4", "sample_group": "EBV transformation into LCL", "timepoint": "week3 following EBV infection"}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.